Earl J. Crain

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

Pancras C. Wong, Earl J. Crain, Bailong Xin et al. · Journal of Thrombosis and Haemostasis · 2008 · 299 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic Therapy

Andrew K. Dilger, Kumar B. Pabbisetty, James R. Corte et al. · Journal of Medicinal Chemistry · 2021 · 97 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits

Pancras C. Wong, Earl J. Crain, Carol A. Watson et al. · Journal of Thrombosis and Thrombolysis · 2011 · 74 citations

Medicine, Hematology, Pharmacology +8

Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits

Pancras C. Wong, Earl J. Crain, Carol A. Watson et al. · Journal of Thrombosis and Haemostasis · 2009 · 68 citations

Medicine, Pharmacology, Pharmacotherapy +15

Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits

Pancras C. Wong, Earl J. Crain, Jeffrey M. Bozarth et al. · Journal of Thrombosis and Haemostasis · 2021 · 61 citations · Full text

Medicine, Hematology, Pharmacology +13